Clopidogrel use in coronary heart disease and percutaneous coronary intervention

Andrew D. Atiemo, Marlene S. Williams

Research output: Contribution to journalReview articlepeer-review


Antiplatelet therapy has proven efficacy in the management of atherothrombosis. Clopidogrel, a thienopyridine, is a potent antiplatelet agent that achieves its antiplatelet effects by inhibiting the binding of adenosine 5' diphos-phate to its platelet receptor. Large clinical trials have demonstrated a role for clopidogrel in the management of symptomatic atherosclerosis, acute coronary syndromes, and patients undergoing percutaneous coronary intervention. In this review, we discuss the pharmacology of clopidogrel including the mechanism of action, review the major clinical trials that have defined the current role of clopidogrel in coronary heart disease and percutaneous coronary intervention, and, finally, examine the concept of clopidogrel resistance and its potential clinical implications.

Original languageEnglish (US)
Pages (from-to)689-700
Number of pages12
JournalJournal of Investigative Medicine
Issue number4
StatePublished - Apr 2008


  • CAD
  • Clopidrogel
  • Platelets

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Clopidogrel use in coronary heart disease and percutaneous coronary intervention'. Together they form a unique fingerprint.

Cite this